NASDAQ:NLSP NLS Pharmaceutics (NLSP) Stock Price, News & Analysis $2.00 -0.12 (-5.66%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.98 -0.01 (-0.75%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About NLS Pharmaceutics Stock (NASDAQ:NLSP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NLS Pharmaceutics alerts:Sign Up Key Stats Today's Range$1.97▼$2.1350-Day Range$1.80▼$2.7952-Week Range$1.30▼$5.64Volume244,951 shsAverage Volume929,918 shsMarket Capitalization$7.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview NLS Pharmaceutics (NASDAQ: NLSP) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period. The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia. Its lead candidate has advanced into mid-stage clinical trials, where the company is evaluating safety, tolerability and efficacy in patients experiencing severe disruptions in their sleep-wake patterns. Preclinical programs are also exploring additional indications in related neurophysiological and metabolic conditions. Founded in 2015, NLS Pharmaceutics has built a research platform that integrates advanced pharmacokinetic modeling with circadian biology to enhance therapeutic outcomes. The company collaborates with academic institutions and sleep-medicine centers in North America and Europe to support patient recruitment and biomarker development. Through these partnerships, NLS Pharmaceutics aims to accelerate proof-of-concept studies and bring innovative treatments to market more efficiently. NLS Pharmaceutics is led by an executive team with extensive experience in drug discovery, clinical development and regulatory affairs. The company’s strategy centers on addressing underserved patient populations and leveraging its circadian platform to expand into new therapeutic areas. By focusing on precise modulation of biological rhythms, NLS Pharmaceutics seeks to deliver differentiated therapies that improve quality of life for patients with chronic sleep and circadian disorders.AI Generated. May Contain Errors. Read More Receive NLSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NLSP Stock News HeadlinesNLS Pharmaceutics stock tumbles after merger approval with KadimastemSeptember 30, 2025 | za.investing.comNLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General MeetingSeptember 30, 2025 | prnewswire.comGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" Eifrig says history shows it could be on the verge of its biggest bull run in over half a century. | Stansberry Research (Ad)NLS Pharmaceutics (NASDAQ:NLSP) Stock Rating Upgraded by Wall Street ZenSeptember 28, 2025 | americanbankingnews.comNLS Pharmaceutics files to sell 5M common shares for holdersSeptember 25, 2025 | msn.comNLS Pharmaceutics Engages New Accounting Firm After Marcum’s ResignationSeptember 19, 2025 | tipranks.comKadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed MergerSeptember 10, 2025 | prnewswire.comNLS Pharmaceutics and Kadimastem Secure Hong Kong Patent for Diabetes TherapySeptember 4, 2025 | msn.comSee More Headlines NLSP Stock Analysis - Frequently Asked Questions How have NLSP shares performed this year? NLS Pharmaceutics' stock was trading at $2.11 at the beginning of 2025. Since then, NLSP stock has decreased by 5.2% and is now trading at $2.00. When did NLS Pharmaceutics IPO? NLS Pharmaceutics (NLSP) raised $20 million in an initial public offering (IPO) on Friday, January 29th 2021. The company issued 3,600,000 shares at a price of $5.00-$6.00 per share. Maxim Group LLC acted as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager. How do I buy shares of NLS Pharmaceutics? Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NLS Pharmaceutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NLS Pharmaceutics investors own include Intel (INTC), Meta Platforms (META), Immunic (IMUX), Seres Therapeutics (MCRB), NVIDIA (NVDA), Tesla (TSLA). Company Calendar Today10/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NLSP CIK1783036 Webwww.nlspharma.com Phone41-44-512-2150Fax41-41-618-8009Employees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.37) per share Price / Book-5.41Miscellaneous Outstanding Shares3,600,000Free Float3,008,000Market Cap$7.20 million OptionableNot Optionable Beta0.14 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:NLSP) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThis soon could be the most precious company in AmericaCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.